Trial Profile
Clinical outcomes of patients with recurrent HER2-positive breast cancer after exposure to adjuvant trastuzumab
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Sep 2014
Price :
$35
*
At a glance
- Drugs Trastuzumab (Primary)
- Indications Breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
- 01 Sep 2014 New trial record